Inhibitors: Difference between revisions
From Proteopedia
Jump to navigationJump to search
New page: <StructureSection load='2f1o.pdb' size='350' frame='true' side='right' scene='2f1o/Com_view/2' caption='NADPH dehydrogenase complex with FAD and inhibitor dicoumarol 2f1o'> This is a ... |
No edit summary |
||
| Line 1: | Line 1: | ||
<StructureSection load='2f1o.pdb' size='350' frame='true' side='right' scene='2f1o/Com_view/2' caption='NADPH dehydrogenase complex with FAD and inhibitor dicoumarol [[2f1o]]'> | <StructureSection load='2f1o.pdb' size='350' frame='true' side='right' scene='2f1o/Com_view/2' caption='NADPH dehydrogenase complex with FAD and inhibitor dicoumarol [[2f1o]]'> | ||
*[[AChE inhibitors and substrates]] | |||
*[[Drug Metabolism by CYP450 Enzymes]] | |||
*In a ''substrate reduction therapy'' a small molecule inhibitor ([[Acid beta-glucosidase with N-nonyl-deoxynojirimycin|Zavesca™]]) is used to inhibit the synthesis of the accumulated glucosylceramide. | |||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||
Revision as of 10:16, 17 October 2021
| ||||||||||||